Literature DB >> 23928118

White matter integrity and executive abilities following treatment with tetrahydrobiopterin (BH4) in individuals with phenylketonuria.

Desirée A White1, Jo Ann V Antenor-Dorsey, Dorothy K Grange, Tamara Hershey, Jerrel Rutlin, Joshua S Shimony, Robert C McKinstry, Shawn E Christ.   

Abstract

Tetrahydrobiopterin (BH(4)) lowers blood phenylalanine (Phe) in individuals with PKU who are responders, but its effects on the brain and cognition have not been explored thoroughly. We examined blood Phe, microstructural white matter integrity, and executive abilities in 12 BH(4) responders before (i.e., baseline) and after (i.e., follow-up) six months of treatment with BH(4). Compared with baseline, Phe in these responders decreased by 51% during a 4 week screening period after initiation of treatment and remained lowered by 37% over the 6 month follow-up period. Significant improvements in white matter integrity, evaluated by mean diffusivity from diffusion tensor imaging, were also found following six months of treatment. Improvements in executive abilities were not identified, although six months may have been a period too brief for changes in cognition to follow changes in the brain. To our knowledge, our study is the first to explore relationships among Phe, white matter integrity, executive abilities, and BH(4) treatment within a single study.
© 2013.

Entities:  

Keywords:  Diffusion tensor imaging; Executive; Phenylketonuria; Sapropterin; Tetrahydrobiopterin; White matter

Mesh:

Substances:

Year:  2013        PMID: 23928118      PMCID: PMC3832288          DOI: 10.1016/j.ymgme.2013.07.010

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  19 in total

1.  Diffusion-weighted MR imaging in patients with phenylketonuria: relationship between serum phenylalanine levels and ADC values in cerebral white matter.

Authors:  Kinuko Kono; Yoshiyuki Okano; Keiko Nakayama; Yutaka Hase; Sosuke Minamikawa; Nozomi Ozawa; Hiroyuki Yokote; Yuichi Inoue
Journal:  Radiology       Date:  2005-08       Impact factor: 11.105

2.  Normal brain maturation during childhood: developmental trends characterized with diffusion-tensor MR imaging.

Authors:  P Mukherjee; J H Miller; J S Shimony; T E Conturo; B C Lee; C R Almli; R C McKinstry
Journal:  Radiology       Date:  2001-11       Impact factor: 11.105

3.  Tract-based evaluation of white matter damage in individuals with early-treated phenylketonuria.

Authors:  Huiling Peng; Dawn Peck; Desirée A White; Shawn E Christ
Journal:  J Inherit Metab Dis       Date:  2013-09-17       Impact factor: 4.982

4.  Twenty-five years of research on neurocognitive outcomes in early-treated phenylketonuria: intelligence and executive function.

Authors:  Kathryn DeRoche; Marilyn Welsh
Journal:  Dev Neuropsychol       Date:  2008       Impact factor: 2.253

5.  Phenylketonuria: white-matter changes assessed by 3.0-T magnetic resonance (MR) imaging, MR spectroscopy and MR diffusion.

Authors:  T Scarabino; T Popolizio; M Tosetti; D Montanaro; G M Giannatempo; R Terlizzi; S Pollice; A Maiorana; N Maggialetti; A Carriero; V Leuzzi; U Salvolini
Journal:  Radiol Med       Date:  2009-03-10       Impact factor: 3.469

6.  A neuropsychological profile of off-diet adults with phenylketonuria.

Authors:  J J Moyle; A M Fox; M Bynevelt; M Arthur; J R Burnett
Journal:  J Clin Exp Neuropsychol       Date:  2007-05       Impact factor: 2.475

7.  Characterization of white matter alterations in phenylketonuria by magnetic resonance relaxometry and diffusion tensor imaging.

Authors:  Peter Vermathen; Laure Robert-Tissot; Joachim Pietz; Thomas Lutz; Chris Boesch; Roland Kreis
Journal:  Magn Reson Med       Date:  2007-12       Impact factor: 4.668

8.  Magnetic resonance imaging in phenylketonuria: reversal of cerebral white matter change.

Authors:  M A Cleary; J H Walter; J E Wraith; F White; K Tyler; J P Jenkins
Journal:  J Pediatr       Date:  1995-08       Impact factor: 4.406

9.  The pathogenesis of the white matter abnormalities in phenylketonuria. A multimodal 3.0 tesla MRI and magnetic resonance spectroscopy (1H MRS) study.

Authors:  V Leuzzi; M Tosetti; D Montanaro; C Carducci; C Artiola; C Carducci; I Antonozzi; M Burroni; F Carnevale; F Chiarotti; T Popolizio; G M Giannatempo; V D'Alesio; T Scarabino
Journal:  J Inherit Metab Dis       Date:  2007-01-23       Impact factor: 4.750

10.  MR in phenylketonuria-related brain lesions.

Authors:  M Dezortová; M Hájek; J Tintera; L Hejcmanová; E Syková
Journal:  Acta Radiol       Date:  2001-09       Impact factor: 1.701

View more
  10 in total

1.  Variability in phenylalanine control predicts IQ and executive abilities in children with phenylketonuria.

Authors:  Anna Hood; Dorothy K Grange; Shawn E Christ; Robert Steiner; Desirée A White
Journal:  Mol Genet Metab       Date:  2014-01-31       Impact factor: 4.797

2.  Prolonged exposure to high and variable phenylalanine levels over the lifetime predicts brain white matter integrity in children with phenylketonuria.

Authors:  Anna Hood; Jo Ann V Antenor-Dorsey; Jerrel Rutlin; Tamara Hershey; Joshua S Shimony; Robert C McKinstry; Dorothy K Grange; Shawn E Christ; Robert Steiner; Desiree A White
Journal:  Mol Genet Metab       Date:  2014-11-13       Impact factor: 4.797

3.  Brain White Matter Integrity Mediates the Relationship Between Phenylalanine Control and Executive Abilities in Children with Phenylketonuria.

Authors:  Anna Hood; Jerrel Rutlin; Joshua S Shimony; Dorothy K Grange; Desiree A White
Journal:  JIMD Rep       Date:  2016-07-22

Review 4.  The complete European guidelines on phenylketonuria: diagnosis and treatment.

Authors:  A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2017-10-12       Impact factor: 4.123

5.  Novel imaging technologies for genetic diagnoses in the inborn errors of metabolism.

Authors:  Andrea L Gropman; Afrouz Anderson
Journal:  J Transl Genet Genom       Date:  2020-11-13

6.  Pretreatment cognitive and neural differences between sapropterin dihydrochloride responders and non-responders with phenylketonuria.

Authors:  Zoë Hawks; Joshua Shimony; Jerrel Rutlin; Dorothy K Grange; Shawn E Christ; Desirée A White
Journal:  Mol Genet Metab Rep       Date:  2017-02-23

7.  Relationship between age and white matter integrity in children with phenylketonuria.

Authors:  Erika Wesonga; Joshua S Shimony; Jerrel Rutlin; Dorothy K Grange; Desiree A White
Journal:  Mol Genet Metab Rep       Date:  2016-04-08

8.  White matter microstructural damage in early treated phenylketonuric patients.

Authors:  María Julieta González; Mónica Rebollo Polo; Pablo Ripollés; Rosa Gassió; Aída Ormazabal; Cristina Sierra; Roser Colomé Roura; Rafael Artuch; Jaume Campistol
Journal:  Orphanet J Rare Dis       Date:  2018-10-26       Impact factor: 4.123

9.  White and gray matter brain development in children and young adults with phenylketonuria.

Authors:  Zoë Hawks; Anna M Hood; Dov B Lerman-Sinkoff; Joshua S Shimony; Jerrel Rutlin; Daniel Lagoni; Dorothy K Grange; Desirée A White
Journal:  Neuroimage Clin       Date:  2019-07-02       Impact factor: 4.881

10.  Treatment With Tetrahydrobiopterin Improves White Matter Maturation in a Mouse Model for Prenatal Hypoxia in Congenital Heart Disease.

Authors:  Jennifer Romanowicz; Camille Leonetti; Zaenab Dhari; Ludmila Korotcova; Shruti D Ramachandra; Nemanja Saric; Paul D Morton; Shivani Bansal; Amrita Cheema; Vittorio Gallo; Richard A Jonas; Nobuyuki Ishibashi
Journal:  J Am Heart Assoc       Date:  2019-07-23       Impact factor: 5.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.